Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Immunity and Booster Effects of Kanghua HDCV Rabies Vaccine
NCT03774628Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Aug 2018
- Primary completion
- Feb 2019
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Randomised, open-label trial of Rabies vaccine in rabies (2 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Proportion of serum rabies virus neutralizing antibodies to protective levels 10 years after primary vaccination, Geometric mean concentration (GMC) of serum rabies virus neutralizing antibody 10 years after primary vaccination and 4 more. Started Aug 2018; status: completed.
02
Drugs
Rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03774628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774628.